A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs TPI 287 (Primary)
- Indications Medulloblastoma; Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 17 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Apr 2012 Planned End Date changed from 1 Nov 2014 to 1 Nov 2018 as reported by ClinicalTrials.gov.